Sakar Healthcare Limited
Sakar Healthcare Limited Fundamental Analysis
Sakar Healthcare Limited (SAKAR.NS) shows moderate financial fundamentals with a PE ratio of 50.80, profit margin of 12.11%, and ROE of 10.17%. The company generates $2.5B in annual revenue with strong year-over-year growth of 15.19%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 61.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze SAKAR.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakSAKAR.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateSAKAR.NS shows balanced valuation metrics.
Growth Score
ExcellentSAKAR.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentSAKAR.NS maintains a strong and stable balance sheet.
Profitability Score
WeakSAKAR.NS struggles to sustain strong margins.
Key Financial Metrics
Is SAKAR.NS Expensive or Cheap?
P/E Ratio
SAKAR.NS trades at 50.80 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SAKAR.NS's PEG of 0.71 indicates potential undervaluation.
Price to Book
The market values Sakar Healthcare Limited at 4.77 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 20.76 times EBITDA. This signals the market has high growth expectations.
How Well Does SAKAR.NS Make Money?
Net Profit Margin
For every $100 in sales, Sakar Healthcare Limited keeps $12.11 as profit after all expenses.
Operating Margin
Core operations generate 18.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.17 in profit for every $100 of shareholder equity.
ROA
Sakar Healthcare Limited generates $6.34 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sakar Healthcare Limited produces operating cash flow of $302.07M, showing steady but balanced cash generation.
Free Cash Flow
Sakar Healthcare Limited generates weak or negative free cash flow of $31.48M, restricting financial flexibility.
FCF Per Share
Each share generates $1.43 in free cash annually.
FCF Yield
SAKAR.NS converts 0.21% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
50.80
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.71
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.77
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.07
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.17
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.28
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How SAKAR.NS Stacks Against Its Sector Peers
| Metric | SAKAR.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 50.80 | 28.62 | Worse (Expensive) |
| ROE | 10.17% | 788.00% | Weak |
| Net Margin | 12.11% | -48085.00% (disorted) | Strong |
| Debt/Equity | 0.17 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 1.28 | 4.11 | Neutral |
| ROA | 6.34% | -21875.00% (disorted) | Weak |
SAKAR.NS outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sakar Healthcare Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
46.93%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
24.87%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
27.01%
Industry Style: Defensive, Growth, Innovation
High Growth